pyrroles has been researched along with famitinib in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 8 (42.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Diao, X; Gao, Z; Guo, Z; Jiang, H; Xie, C; Zhang, L; Zhong, D; Zhou, J | 1 |
| Chang, C; Chen, X; Jiang, H; Lou, D; Qin, Q; Wang, J; Zhang, W; Zhong, D; Zhou, A | 1 |
| Chang, CX; Jiang, HY; Ma, JH; Qin, Q; Wang, JW; Zhang, W; Zhou, AP | 1 |
| Cao, J; Hu, X; Lv, F; Wang, B; Wang, L; Wang, Z; Zhang, J | 1 |
| Chen, XY; Gao, ZW; Yu, MM; Zhong, DF | 1 |
| Huang, J; Ma, J; Mu, X; Qin, Y; Wu, G; Xu, S; Yang, K; Zhang, Z; Zhou, H | 1 |
| Papaxoinis, G; Saif, MW; Syrigos, K | 1 |
| Ba, Y; Bai, YX; Bi, JW; Ding, KF; Feng, JP; Lei, J; Li, J; Lin, LZ; Liu, YP; Ma, LW; Shen, L; Shi, CM; Wang, D; Wang, JW; Wang, KM; Wu, CP; Wu, G; Xiong, JP; Xu, RH; Yang, Q; Yu, H | 1 |
| Chen, XY; Jiang, JF; Zhong, DF | 1 |
| Chen, W; Gong, X; Liu, S; Tao, X; Wei, H; Xia, T; Zhai, J | 1 |
| Cao, K; Chen, Q; Guo, L; Guo, S; Guo, X; Guo, Y; Han, F; He, Q; Li, Y; Liang, Y; Liu, H; Liu, L; Liu, N; Ma, J; Mai, H; Mo, H; Mo, Y; Sun, R; Sun, X; Tang, L; Tang, Q; Wang, J; Wang, P; Xie, C; Yang, X; Ye, Y; Zeng, M; Zhang, L | 1 |
| Fu, H; Fu, L; Li, Y; Lou, L; Quan, H; Zhang, M | 1 |
| Cai, J; Guo, H; He, C; Luo, H; Qu, YY; Sun, Z; Wang, Q; Xia, S; Xing, N; Ye, DW; Zhang, HL; Zhang, X; Zou, Q | 1 |
| Thomas, T | 1 |
| Gao, Y; Hu, W; Lou, G; Pan, M; Peng, J; Shi, H; Sun, R; Wang, L; Wang, Q; Wu, X; Xia, L; Zhang, Y; Zhou, Q; Zhou, X; Zhu, J | 1 |
| Cao, AY; Chai, WJ; Chen, CM; Chen, L; Chen, X; Di, GH; Fan, L; Guo, X; Hou, YF; Hu, X; Hu, Z; Huang, XY; Jiang, YZ; Li, JJ; Liu, GY; Ma, XY; Shao, ZM; Sun, XJ; Wang, ZH; Wu, J; Wu, SY; Xu, Y; Yang, WT; Yu, KD; Zhao, S; Zhu, XY; Zou, JJ | 1 |
| Loi, S; Salgado, R | 1 |
| Bian, XJ; Cai, J; Chen, C; Han, W; He, C; Luo, H; Qu, YY; Sun, Z; Wang, Q; Xing, N; Ye, DW; Zhang, X; Zou, Q | 1 |
| Cao, Y; Fu, Y; Gao, X; Jiang, X; Li, T; Li, X; Lin, P; Liu, Y; Shi, P; Sun, F; Wang, C; Zhang, Y | 1 |
1 review(s) available for pyrroles and famitinib
| Article | Year |
|---|---|
[Metabolic research of domestically developed small molecule tyrosine kinase inhibitors].
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Benzofurans; China; Crown Ethers; Drug Interactions; Humans; Indoles; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines | 2016 |
7 trial(s) available for pyrroles and famitinib
| Article | Year |
|---|---|
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib.
Topics: Adult; Aged; Angiogenesis Inhibitors; Biotransformation; Carcinoma, Renal Cell; China; Cohort Studies; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Hypertension; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasms; Postprandial Period; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Sarcoma; Young Adult | 2013 |
Famitinib in metastatic renal cell carcinoma: a single center study.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Hypothyroidism as a potential biomarker of efficacy of famitinib, a novel VEGFR-2 inhibitor in metastatic breast cancer.
Topics: Adolescent; Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Female; Follow-Up Studies; Humans; Hypothyroidism; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pyrroles; Survival Rate; Thyrotropin; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2014 |
Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial.
Topics: Administration, Oral; Adult; Aged; Colorectal Neoplasms; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Male; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrroles; Survival Analysis; Treatment Outcome | 2017 |
Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Humans; Indoles; Male; Middle Aged; Nasopharyngeal Carcinoma; Pyrroles; Receptor Protein-Tyrosine Kinases | 2018 |
Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Ovarian Epithelial; Female; Humans; Indoles; Middle Aged; Pyrroles | 2022 |
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Indoles; Male; Platinum; Pyrroles; Urinary Bladder Neoplasms | 2022 |
11 other study(ies) available for pyrroles and famitinib
| Article | Year |
|---|---|
Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Biotransformation; Cytochrome P-450 Enzyme System; Female; Hepatocytes; Humans; Indoles; Isoenzymes; Male; Microsomes, Liver; Middle Aged; Neoplasms; Oxidation-Reduction; Pyrroles; Receptor Protein-Tyrosine Kinases; Tissue Distribution | 2013 |
[Predicting pharmacokinetics of anti-cancer drug, famitinib in human using physiologically based pharmacokinetic model].
Topics: Animals; Antineoplastic Agents; Haplorhini; Humans; Indoles; Models, Biological; Pyrroles; Rats; Receptor Protein-Tyrosine Kinases; Tissue Distribution | 2014 |
Famitinib enhances nasopharyngeal cancer cell radiosensitivity by attenuating radiation-induced phosphorylation of platelet-derived growth factor receptor and c-kit and inhibiting microvessel formation.
Topics: Animals; Carcinoma; Cell Line, Tumor; Female; Humans; Indoles; Mice; Mice, Nude; Microvessels; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrroles; Radiation Tolerance; Receptor, Platelet-Derived Growth Factor beta; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |
Novel therapeutic approaches and mechanisms in neuroendocrine tumors: the role of targeted agents.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials as Topic; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Grading; Neovascularization, Pathologic; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrroles; Signal Transduction; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2016 |
LC-MS/MS method for simultaneous determination of famitinib and its major metabolites in human plasma.
Topics: Blood Chemical Analysis; Calibration; Chromatography, Liquid; Feasibility Studies; Humans; Indoles; Limit of Detection; Pyrroles; Reproducibility of Results; Tandem Mass Spectrometry; Time Factors | 2018 |
Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Protein Kinase Inhibitors; Pyrroles; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2021 |
Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles | 2021 |
Camrelizumab plus famitinib to treat RCC.
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Pyrroles | 2021 |
Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Humans; Indoles; Paclitaxel; Pyrroles; Triple Negative Breast Neoplasms | 2022 |
What's in a Name? That Which We Call Immune Cells by Any Other Name Would All Smell as Sweet.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Humans; Indoles; Paclitaxel; Pyrroles; Triple Negative Breast Neoplasms | 2022 |
The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.
Topics: Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Drug Interactions; Healthy Volunteers; Humans; Indoles; Male; Pyrroles; Rifampin; Tandem Mass Spectrometry | 2022 |